$CAPR,,,Just watching right now,,,low volume,,,not
Post# of 23077
(Total Views: 929)
Posted On: 05/27/2017 10:17:22 AM
$CAPR,,,Just watching right now,,,low volume,,,not great news,,,hit it's all time low on 5/25 @ $.72,,, closed Friday @ $.82,,, the daily chart was all over but seems it now has support at $.80 with resistance showing on my chart @ $.83,,,for some reason,,,one of my charting services shows that it will open Tuesday @ $.85. I will have my eyes on this all day Tuesday as it appears this may be a good time to buy if volume will cooperate. Apparently only in my opinion as everywhere I checked says "Sell,,,Sell,,,Sell..."
Capricor Therapeutics logoCapricor Therapeutics Inc (OTCMKTS:CAPR) Director Louis Manzo bought 10,000 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were acquired at an average price of $3.10 per share, with a total value of $31,000.00. Following the transaction, the director now owns 138,384 shares of the company’s stock, valued at approximately $428,990.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Capricor Therapeutics Inc (OTCMKTS:CAPR) traded down 1.20% during trading on Friday, hitting $0.82. 114,861 shares of the stock traded hands. The stock’s market cap is $17.55 million. Capricor Therapeutics Inc has a 52 week low of $0.72 and a 52 week high of $5.40. The firm’s 50-day moving average is $2.48 and its 200 day moving average is $2.72.
Capricor Therapeutics (OTCMKTS:CAPR) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $0.87 million. Equities research analysts forecast that Capricor Therapeutics Inc will post ($0.74) earnings per share for the current fiscal year.
CAPR has been the subject of several research reports. Zacks Investment Research downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. HC Wainwright set a $14.00 target price on shares of Capricor Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 16th. Finally, Rodman & Renshaw started coverage on shares of Capricor Therapeutics in a report on Monday, February 13th. They issued a “buy” rating and a $14.00 price target on the stock.
A hedge fund recently raised its stake in Capricor Therapeutics stock. Geode Capital Management LLC boosted its stake in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,387 shares of the biotechnology company’s stock after buying an additional 2,458 shares during the period. Geode Capital Management LLC’s holdings in Capricor Therapeutics were worth $154,000 at the end of the most recent reporting period.
About Capricor Therapeutics:
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Capricor Therapeutics logoCapricor Therapeutics Inc (OTCMKTS:CAPR) Director Louis Manzo bought 10,000 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were acquired at an average price of $3.10 per share, with a total value of $31,000.00. Following the transaction, the director now owns 138,384 shares of the company’s stock, valued at approximately $428,990.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Capricor Therapeutics Inc (OTCMKTS:CAPR) traded down 1.20% during trading on Friday, hitting $0.82. 114,861 shares of the stock traded hands. The stock’s market cap is $17.55 million. Capricor Therapeutics Inc has a 52 week low of $0.72 and a 52 week high of $5.40. The firm’s 50-day moving average is $2.48 and its 200 day moving average is $2.72.
Capricor Therapeutics (OTCMKTS:CAPR) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $0.87 million. Equities research analysts forecast that Capricor Therapeutics Inc will post ($0.74) earnings per share for the current fiscal year.
CAPR has been the subject of several research reports. Zacks Investment Research downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. HC Wainwright set a $14.00 target price on shares of Capricor Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 16th. Finally, Rodman & Renshaw started coverage on shares of Capricor Therapeutics in a report on Monday, February 13th. They issued a “buy” rating and a $14.00 price target on the stock.
A hedge fund recently raised its stake in Capricor Therapeutics stock. Geode Capital Management LLC boosted its stake in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,387 shares of the biotechnology company’s stock after buying an additional 2,458 shares during the period. Geode Capital Management LLC’s holdings in Capricor Therapeutics were worth $154,000 at the end of the most recent reporting period.
About Capricor Therapeutics:
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280